Discovery of a first-in-class ANXA3 degrader for the treatment of triple-negative breast cancer
Triple-negative breast cancer (TNBC) is a nasty disease with extremely high malignancy and poor prognosis. Annexin A3 (ANXA3) is a potential prognosis biomarker, displaying an excellent correlation of ANXA3 overexpression with patients' poor prognosis. Silencing the expression of ANXA3 effectively i...
Uloženo v:
| Hlavní autoři: | , , , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Elsevier
2023-04-01
|
| Edice: | Acta Pharmaceutica Sinica B |
| Témata: | |
| On-line přístup: | http://www.sciencedirect.com/science/article/pii/S2211383522004907 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|